Opiant Pharmaceuticals Inc (OPNT):企業の財務・戦略的SWOT分析

◆英語タイトル:Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0589
◆発行会社(調査会社):GlobalData
◆発行日:2019年12月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Opiant Pharmaceuticals Inc (OPNT) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc Key Recent Developments

Nov 12,2019: Opiant Pharmaceuticals reports third quarter 2019 financial results and provides corporate update
Oct 10,2019: Opiant Pharmaceuticals to host a research & development meeting on emerging therapeutics for the treatment of addiction and drug overdose
Sep 17,2019: Opiant Pharmaceuticals strengthens management team with appointments of Chief Commercial Officer and General Counsel
Aug 08,2019: Opiant Pharmaceuticals reports second quarter 2019 financial results and provides corporate update
May 09,2019: Opiant Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Opiant Pharmaceuticals Inc – Key Facts
Opiant Pharmaceuticals Inc – Key Employees
Opiant Pharmaceuticals Inc – Key Employee Biographies
Opiant Pharmaceuticals Inc – Major Products and Services
Opiant Pharmaceuticals Inc – History
Opiant Pharmaceuticals Inc – Company Statement
Opiant Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Opiant Pharmaceuticals Inc – Business Description
Opiant Pharmaceuticals Inc – Corporate Strategy
Opiant Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Opiant Pharmaceuticals Inc – Strengths
Opiant Pharmaceuticals Inc – Weaknesses
Opiant Pharmaceuticals Inc – Opportunities
Opiant Pharmaceuticals Inc – Threats
Opiant Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Opiant Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 12, 2019: Opiant Pharmaceuticals reports third quarter 2019 financial results and provides corporate update
Oct 10, 2019: Opiant Pharmaceuticals to host a research & development meeting on emerging therapeutics for the treatment of addiction and drug overdose
Sep 17, 2019: Opiant Pharmaceuticals strengthens management team with appointments of Chief Commercial Officer and General Counsel
Aug 08, 2019: Opiant Pharmaceuticals reports second quarter 2019 financial results and provides corporate update
May 09, 2019: Opiant Pharmaceuticals reports first quarter 2019 financial results and provides corporate update
Mar 21, 2019: Opiant Pharmaceuticals reports fourth quarter and full-year 2018 financial results and provides corporate update
Dec 27, 2018: Opiant and Sanofi sign licensing deal for drinabant
Nov 07, 2018: Opiant Pharmaceuticals announces third quarter 2018 financial results
Oct 29, 2018: Opiant Pharmaceuticals names Craig Collard to Board of Directors
Sep 20, 2018: HHS sponsors development of intranasal form of long-acting opioid overdose drug
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Opiant Pharmaceuticals Inc, Key Facts
Opiant Pharmaceuticals Inc, Key Employees
Opiant Pharmaceuticals Inc, Key Employee Biographies
Opiant Pharmaceuticals Inc, Major Products and Services
Opiant Pharmaceuticals Inc, History
Opiant Pharmaceuticals Inc, Subsidiaries
Opiant Pharmaceuticals Inc, Key Competitors
Opiant Pharmaceuticals Inc, Ratios based on current share price
Opiant Pharmaceuticals Inc, Annual Ratios
Opiant Pharmaceuticals Inc, Annual Ratios (Cont...1)
Opiant Pharmaceuticals Inc, Annual Ratios (Cont...2)
Opiant Pharmaceuticals Inc, Interim Ratios
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Opiant Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Opiant Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Opiant Pharmaceuticals Inc, Ratio Charts
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Opiant Pharmaceuticals Inc (OPNT):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wenzel Downhole Tools Ltd:企業の戦略的SWOT分析
    Wenzel Downhole Tools Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Renk AG (ZAR):企業の財務・戦略的SWOT分析
    Renk AG (ZAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Kazanorgsintez (KZOS):企業の財務・戦略的SWOT分析
    Kazanorgsintez (KZOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Silver Spring Networks, Inc. (SSNI)-エネルギー分野:企業M&A・提携分析
    Summary Silver Spring Networks, Inc. (Silver Spring) is a smart grid networking platform technology and solutions provider. The company’s products include metering devices, network infrastructure, utilityIQ applications, GridScape software and customerIQ web portal. Silver Spring provides wide range …
  • Omnicell Inc (OMCL)-医療機器分野:企業M&A・提携分析
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • Alacer Gold Corp:企業の戦略・SWOT・財務情報
    Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nexira:企業の戦略・SWOT・財務情報
    Nexira - Strategy, SWOT and Corporate Finance Report Summary Nexira - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • SoftBank Group Corporation:企業のM&A・事業提携・投資動向
    SoftBank Group Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SoftBank Group Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Warp Drive Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary Warp Drive Bio Inc (Warp Drive) is a natural products provider. The company utilizes the proprietary genomic mining and small molecule assisted receptor targeting platform to develop novel medicines. Its SMART platform offers solutions to the pharmaceutical opportunities. Warp Drive's integr …
  • Bone Biologics Corp (BBLG):医療機器:M&Aディール及び事業提携情報
    Summary Bone Biologics Corp (Bone Biologics) is a biotechnology company that develops orthobiologic products. The company develops NELL-1, a recombinant human protein growth factor, which is essential for normal bone development. It offers bone graft substitutes for spine fusion. Bone Biologics also …
  • Britvic Plc:戦略・SWOT・企業財務分析
    Britvic Plc - Strategy, SWOT and Corporate Finance Report Summary Britvic Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Group Five Ltd:企業の戦略的SWOT分析
    Group Five Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Xylem Inc.:企業の戦略・SWOT・財務情報
    Xylem Inc. - Strategy, SWOT and Corporate Finance Report Summary Xylem Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • National Instruments Corp (NATI):企業の財務・戦略的SWOT分析
    National Instruments Corp (NATI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company's pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various valid …
  • Wabash Valley Power Association, Inc.:企業の戦略的SWOT分析
    Wabash Valley Power Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • The Castle Group, Inc.:企業の戦略・SWOT・財務情報
    The Castle Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Castle Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Cyclacel Pharmaceuticals Inc (CYCC):企業の財務・戦略的SWOT分析
    Cyclacel Pharmaceuticals Inc (CYCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • PT. Bank Rakyat Indonesia (Persero) Tbk.:戦略・SWOT・企業財務分析
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆